{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Binding Antibody Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Neutralizing Antibody Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies.\n\nParticipants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.","groups":[{"description":"One 4-week cycle of blinatumomab 15 μg/m\\^2/day as a continuous intravenous infusion (CIVI).","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set: participants who received protocol-specified therapy analyzed according to the treatment they received. Participants in the blinatumumab arm with a post-baseline result.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 29.","title":"Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)","type":"SECONDARY","unitOfMeasure":"participants"}